Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP
Peter Lin MD, CCFP Associate Editor
Chill Yee MD
Chill C. Yee MD Advisory Board
David Rakel MD, FAAFP
David Rakel MD, FAAFP Editor-in-Chief
See All Experts
featured
Published in Primary Care and
1 other channel

Journal Scan / Research · August 22, 2018

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily in Type 2 Diabetes

Diabetes Care

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Richard Pratley MD

Diabetes Care
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Diabetes Care 2018 Aug 06;[EPub Ahead of Print], SA Jabbour, JP Frìas, E Hardy, A Ahmed, H Wang, P Öhman, C Guja

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated